Detalles de la búsqueda
1.
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.
N Engl J Med
; 378(22): 2078-2092, 2018 May 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-29658856
2.
Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
Lancet Oncol
; 21(3): 387-397, 2020 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-32035514
3.
A phase 1 dose-escalation study of checkpoint kinase 1 (CHK1) inhibitor prexasertib in combination with p38 mitogen-activated protein kinase (p38 MAPK) inhibitor ralimetinib in patients with advanced or metastatic cancer.
Invest New Drugs
; 38(4): 1145-1155, 2020 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-31707688
4.
Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study.
J Clin Oncol
; 41(11): 1992-1998, 2023 04 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-36809080
5.
Combined treatment of nonsmall cell lung cancer NSCLC stage III with intensity-modulated RT radiotherapy and cetuximab: the NEAR trial.
Cancer
; 117(13): 2986-94, 2011 Jul 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-21264838
6.
Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer.
J Clin Oncol
; 38(14): 1505-1517, 2020 05 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-32150489
7.
Randomized study to evaluate the use of high-dose therapy as part of primary treatment for "aggressive" lymphoma.
J Clin Oncol
; 20(22): 4413-9, 2002 Nov 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-12431962
8.
Cross-market cost-effectiveness analysis of erlotinib as first-line maintenance treatment for patients with stable non-small cell lung cancer.
Clinicoecon Outcomes Res
; 4: 31-7, 2012.
Artículo
en Inglés
| MEDLINE | ID: mdl-22347803
9.
The gefitinib long-term responder (LTR)--a cancer stem-like cell story? Insights from molecular analyses of German long-term responders treated in the IRESSA expanded access program (EAP).
Lung Cancer
; 77(1): 183-91, 2012 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-22483783
10.
Costs of bevacizumab and pemetrexed for advanced non-squamous NSCLC in Italy and Germany.
Lung Cancer
; 69 Suppl 1: S18-23, 2010 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-20727458
11.
Observation of the treatment and outcomes of patients receiving chemotherapy for advanced NSCLC in Europe (ACTION study).
Curr Med Res Opin
; 26(6): 1461-70, 2010 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-20394472
12.
Societal cost savings through bevacizumab-based treatment in non-small cell lung cancer (NSCLC).
Lung Cancer
; 69 Suppl 1: S24-30, 2010 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-20727459
13.
Effectiveness of bevacizumab- and pemetrexed-cisplatin treatment for patients with advanced non-squamous non-small cell lung cancer.
Lung Cancer
; 69 Suppl 1: S4-10, 2010 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-20727460
Resultados
1 -
13
de 13
1
Próxima >
>>